STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] BlackRock Capital Allocation Term Trust SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly filed Amendment No. 21 to their Schedule 13D on BlackRock Capital Allocation Term Trust (ticker BCAT).

  • Ownership disclosed: 5,352,474 – 5,352,475 common shares, equal to 5.11 % of the 104,775,271 shares outstanding as of 5/19/25.
  • Voting/Dispositive power: 0 sole; full power is shared among the reporting persons.
  • Cost basis: approximately $78.4 million in aggregate consideration, funded with investor capital and ordinary-course margin borrowings.
  • Transaction window: open-market purchases between 7/14/25 and 7/24/25 prompted the filing.
  • Purpose of transaction: “Not Applicable”; no specific strategic intentions or agreements were disclosed (Items 4 & 6).

The filing converts the group from passive (13G) to active (13D) status and updates Items 3, 5 and 7. No criminal or civil proceedings are reported against the filers, and signature authority is provided by General Counsel Michael D’Angelo.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Saba’s filing shows a new 5.1 % position in BCAT; no stated agenda but 13D status suggests optional activism.

The switch from a 13G to a 13D indicates Saba now reserves the right to influence BCAT. Although no plans were detailed, accumulating a >5 % stake worth $78 million positions the hedge fund to pressure management on discount-to-NAV issues common in closed-end funds. The ownership is shared across Saba-managed funds, giving them voting leverage without sole control. For investors, the entry of an experienced credit CEF specialist can act as a catalyst for narrowing discounts, but the absence of an explicit campaign tempers immediate impact.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 104,775,271 shares of common stock outstanding as of 5/19/25, as disclosed in the company's DEF 14A filed with the Securities and Exchange Commission on 5/22/25.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 104,775,271 shares of common stock outstanding as of 5/19/25, as disclosed in the company's DEF 14A filed with the Securities and Exchange Commission on 5/22/25.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 104,775,271 shares of common stock outstanding as of 5/19/25, as disclosed in the company's DEF 14A filed with the Securities and Exchange Commission on 5/22/25.


SCHEDULE 13D


Saba Capital Management, L.P.
Signature:/s/ Michael D'Angelo
Name/Title:General Counsel
Date:07/28/2025
Boaz R. Weinstein
Signature:/s/ Michael D'Angelo
Name/Title:Authorized Signatory
Date:07/28/2025
Saba Capital Management GP, LLC
Signature:/s/ Michael D'Angelo
Name/Title:Attorney-in-fact*
Date:07/28/2025
Comments accompanying signature:
Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823

FAQ

How many BCAT shares does Saba Capital now own?

The filing reports 5,352,474–5,352,475 common shares, equal to 5.11 % of shares outstanding.

What was the cost of Saba’s BCAT position?

Approximately $78.4 million in aggregate purchase consideration.

Why did Saba file a Schedule 13D instead of 13G?

Owning more than 5 % and switching to a 13D allows Saba to take actions that may influence BCAT, though no plans were disclosed.

Does Saba have sole voting power over the BCAT shares?

No. The filing states 0 sole voting/dispositive power; all power is shared among the reporting persons.

When were the latest BCAT purchases made by Saba?

Open-market transactions occurred between 7/14/25 and 7/24/25.
BlackRock Capital Allocation Term ord

NYSE:BCAT

BCAT Rankings

BCAT Latest News

BCAT Latest SEC Filings

BCAT Stock Data

1.52B
107.46M
0.01%
21.76%
0.12%
Asset Management
Financial Services
United States
New York